Literature DB >> 16127013

Anti-inflammatory and immune regulatory properties of 5-androsten-3beta, 17beta-diol (HE2100), and synthetic analogue HE3204: implications for treatment of autoimmune diseases.

D Auci1, F Nicoletti, K Mangano, R Pieters, S Nierkens, L Morgan, H Offner, J Frincke, C Reading.   

Abstract

5-Androsten-3beta, 17beta-diol (HE2100), and a synthetic analogue HE3204 are regarded as immune-regulating hormones, because both induce changes in the reporter antigen-popliteal lymph node assay (RA-PLNA). Mice were injected in the footpad with either HE2100 or HE3204 (0.01-3 mg), and a nonsensitizing dose of trinitrophenyl ovalbumin (TNP-OVA) was used as bystander reporter antigen. Seven days later, nodes were removed and numbers of cells (CD3, CD4, CD8, CD19; flow cytometry), TNP-specific IgM, IgG1, and IgG2a antibody-forming cells (AFCs; ELISPOT assay), and cytokines (interleukin-4 [IL-4], interferon-gamma [IFN-gamma]; ELISA) were measured. HE2100 and HE3204 increased cell numbers in a dose-dependent fashion. T (helper and suppressor) cells and B cells were increased (>5-fold). HE3204 was apparently twice as potent as HE2100. Both increased the B/T ratio (fivefold), increased TNP-specific IgM and IgG1 ( approximately 50-fold), and induced IgG2a AFCs. Both increased IL-4 and IFN-gamma secretion (up to threefold). Both displayed anti-inflammatory activity in the murine model of carrageenan-induced pleurisy, as evidenced by reduced neutrophil numbers and exudate volumes. Our observations suggest that both HE2100 and HE3204 are immune-regulating steroid hormones that exhibit anti-inflammatory properties. HE2100 (1 mg/mouse per day) provided significant benefit when given at disease onset in the SJL/J female mouse model of experimental autoimmune encephalomyelitis. These compounds and their analogues are candidates for further testing in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127013     DOI: 10.1196/annals.1361.117

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Phase I and Phase II clinical trials of androst-5-ene-3β,7β,17β-triol.

Authors:  Dwight R Stickney; Clarence N Ahlem; Elizabeth Morgan; Christopher L Reading; Nanette Onizuka; James M Frincke
Journal:  Am J Transl Res       Date:  2011-04-12       Impact factor: 4.060

2.  Studies of the pharmacology of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol, a synthetic anti-inflammatory androstene.

Authors:  Clarence N Ahlem; Michael R Kennedy; Theodore M Page; Christopher L Reading; Steven K White; John J McKenzie; Phaedra I Cole; Dwight R Stickney; James M Frincke
Journal:  Int J Clin Exp Med       Date:  2011-04-23

3.  5-androstenediol ameliorates pleurisy, septic shock, and experimental autoimmune encephalomyelitis in mice.

Authors:  Ferdinando Nicoletti; Dominick L Auci; Katia Mangano; Jaime Flores-Riveros; Sonia Villegas; James M Frincke; Christopher L Reading; Halina Offner
Journal:  Autoimmune Dis       Date:  2010-05-18

4.  Androstenediol Reduces Demyelination-Induced Axonopathy in the Rat Corpus Callosum: Impact on Microglial Polarization.

Authors:  Samah Kalakh; Abdeslam Mouihate
Journal:  Front Cell Neurosci       Date:  2017-02-23       Impact factor: 5.505

5.  5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis.

Authors:  Marcy B Grace; Vijay K Singh; Juong G Rhee; William E Jackson; Tzu-Cheg Kao; Mark H Whitnall
Journal:  J Radiat Res       Date:  2012-07-22       Impact factor: 2.724

6.  Alteration of the steroidogenesis in boys with autism spectrum disorders.

Authors:  Katarína Janšáková; Martin Hill; Diana Čelárová; Hana Celušáková; Gabriela Repiská; Marie Bičíková; Ludmila Máčová; Daniela Ostatníková
Journal:  Transl Psychiatry       Date:  2020-10-06       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.